- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
The Tardive Dyskinesia (TD) Treatment Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Tardive Dyskinesia (TD) Treatment Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospitals accounting for % of the Tardive Dyskinesia (TD) Treatment Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Valbenazine segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Tardive Dyskinesia (TD) Treatment Drugs include Neurocrine Biosciences, Inc., Teva Pharmaceutical Industries, Pfizer Inc., Biogen, and Novartis AG, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Tardive Dyskinesia (TD) Treatment Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Valbenazine
Deutetrabenazine
Market segment by Application, can be divided into
Hospitals
Clinic
Others
Market segment by players, this report covers
Neurocrine Biosciences, Inc.
Teva Pharmaceutical Industries
Pfizer Inc.
Biogen
Novartis AG
AstraZeneca
GlaxoSmithKline plc.
Bayer AG
Sanofi
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Tardive Dyskinesia (TD) Treatment Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Tardive Dyskinesia (TD) Treatment Drugs, with revenue, gross margin and global market share of Tardive Dyskinesia (TD) Treatment Drugs from 2019 to 2022.
Chapter 3, the Tardive Dyskinesia (TD) Treatment Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Tardive Dyskinesia (TD) Treatment Drugs market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Tardive Dyskinesia (TD) Treatment Drugs research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1 Market Overview
1.1 Product Overview and Scope of Tardive Dyskinesia (TD) Treatment Drugs
1.2 Classification of Tardive Dyskinesia (TD) Treatment Drugs by Type
1.2.1 Overview: Global Tardive Dyskinesia (TD) Treatment Drugs Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Tardive Dyskinesia (TD) Treatment Drugs Revenue Market Share by Type in 2021
1.2.3 Valbenazine
1.2.4 Deutetrabenazine
1.3 Global Tardive Dyskinesia (TD) Treatment Drugs Market by Application
1.3.1 Overview: Global Tardive Dyskinesia (TD) Treatment Drugs Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Global Tardive Dyskinesia (TD) Treatment Drugs Market Size & Forecast
1.5 Global Tardive Dyskinesia (TD) Treatment Drugs Market Size and Forecast by Region
1.5.1 Global Tardive Dyskinesia (TD) Treatment Drugs Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Tardive Dyskinesia (TD) Treatment Drugs Market Size by Region, (2017-2022)
1.5.3 North America Tardive Dyskinesia (TD) Treatment Drugs Market Size and Prospect (2017-2028)
1.5.4 Europe Tardive Dyskinesia (TD) Treatment Drugs Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Tardive Dyskinesia (TD) Treatment Drugs Market Size and Prospect (2017-2028)
1.5.6 South America Tardive Dyskinesia (TD) Treatment Drugs Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Tardive Dyskinesia (TD) Treatment Drugs Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Tardive Dyskinesia (TD) Treatment Drugs Market Drivers
1.6.2 Tardive Dyskinesia (TD) Treatment Drugs Market Restraints
1.6.3 Tardive Dyskinesia (TD) Treatment Drugs Trends Analysis
2 Company Profiles
2 Company Profiles
2.1 Neurocrine Biosciences, Inc.
2.1.1 Neurocrine Biosciences, Inc. Details
2.1.2 Neurocrine Biosciences, Inc. Major Business
2.1.3 Neurocrine Biosciences, Inc. Tardive Dyskinesia (TD) Treatment Drugs Product and Solutions
2.1.4 Neurocrine Biosciences, Inc. Tardive Dyskinesia (TD) Treatment Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Neurocrine Biosciences, Inc. Recent Developments and Future Plans
2.2 Teva Pharmaceutical Industries
2.2.1 Teva Pharmaceutical Industries Details
2.2.2 Teva Pharmaceutical Industries Major Business
2.2.3 Teva Pharmaceutical Industries Tardive Dyskinesia (TD) Treatment Drugs Product and Solutions
2.2.4 Teva Pharmaceutical Industries Tardive Dyskinesia (TD) Treatment Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Teva Pharmaceutical Industries Recent Developments and Future Plans
2.3 Pfizer Inc.
2.3.1 Pfizer Inc. Details
2.3.2 Pfizer Inc. Major Business
2.3.3 Pfizer Inc. Tardive Dyskinesia (TD) Treatment Drugs Product and Solutions
2.3.4 Pfizer Inc. Tardive Dyskinesia (TD) Treatment Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Pfizer Inc. Recent Developments and Future Plans
2.4 Biogen
2.4.1 Biogen Details
2.4.2 Biogen Major Business
2.4.3 Biogen Tardive Dyskinesia (TD) Treatment Drugs Product and Solutions
2.4.4 Biogen Tardive Dyskinesia (TD) Treatment Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Biogen Recent Developments and Future Plans
2.5 Novartis AG
2.5.1 Novartis AG Details
2.5.2 Novartis AG Major Business
2.5.3 Novartis AG Tardive Dyskinesia (TD) Treatment Drugs Product and Solutions
2.5.4 Novartis AG Tardive Dyskinesia (TD) Treatment Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Novartis AG Recent Developments and Future Plans
2.6 AstraZeneca
2.6.1 AstraZeneca Details
2.6.2 AstraZeneca Major Business
2.6.3 AstraZeneca Tardive Dyskinesia (TD) Treatment Drugs Product and Solutions
2.6.4 AstraZeneca Tardive Dyskinesia (TD) Treatment Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 AstraZeneca Recent Developments and Future Plans
2.7 GlaxoSmithKline plc.
2.7.1 GlaxoSmithKline plc. Details
2.7.2 GlaxoSmithKline plc. Major Business
2.7.3 GlaxoSmithKline plc. Tardive Dyskinesia (TD) Treatment Drugs Product and Solutions
2.7.4 GlaxoSmithKline plc. Tardive Dyskinesia (TD) Treatment Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 GlaxoSmithKline plc. Recent Developments and Future Plans
2.8 Bayer AG
2.8.1 Bayer AG Details
2.8.2 Bayer AG Major Business
2.8.3 Bayer AG Tardive Dyskinesia (TD) Treatment Drugs Product and Solutions
2.8.4 Bayer AG Tardive Dyskinesia (TD) Treatment Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Bayer AG Recent Developments and Future Plans
2.9 Sanofi
2.9.1 Sanofi Details
2.9.2 Sanofi Major Business
2.9.3 Sanofi Tardive Dyskinesia (TD) Treatment Drugs Product and Solutions
2.9.4 Sanofi Tardive Dyskinesia (TD) Treatment Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Sanofi Recent Developments and Future Plans
3 Market Competition, by Players
3 Market Competition, by Players
3.1 Global Tardive Dyskinesia (TD) Treatment Drugs Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Tardive Dyskinesia (TD) Treatment Drugs Players Market Share in 2021
3.2.2 Top 10 Tardive Dyskinesia (TD) Treatment Drugs Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Tardive Dyskinesia (TD) Treatment Drugs Players Head Office, Products and Services Provided
3.4 Tardive Dyskinesia (TD) Treatment Drugs Mergers & Acquisitions
3.5 Tardive Dyskinesia (TD) Treatment Drugs New Entrants and Expansion Plans
4 Market Size Segment by Type
4 Market Size Segment by Type
4.1 Global Tardive Dyskinesia (TD) Treatment Drugs Revenue and Market Share by Type (2017-2022)
4.2 Global Tardive Dyskinesia (TD) Treatment Drugs Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5 Market Size Segment by Application
5.1 Global Tardive Dyskinesia (TD) Treatment Drugs Revenue Market Share by Application (2017-2022)
5.2 Global Tardive Dyskinesia (TD) Treatment Drugs Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6 North America by Country, by Type, and by Application
6.1 North America Tardive Dyskinesia (TD) Treatment Drugs Revenue by Type (2017-2028)
6.2 North America Tardive Dyskinesia (TD) Treatment Drugs Revenue by Application (2017-2028)
6.3 North America Tardive Dyskinesia (TD) Treatment Drugs Market Size by Country
6.3.1 North America Tardive Dyskinesia (TD) Treatment Drugs Revenue by Country (2017-2028)
6.3.2 United States Tardive Dyskinesia (TD) Treatment Drugs Market Size and Forecast (2017-2028)
6.3.3 Canada Tardive Dyskinesia (TD) Treatment Drugs Market Size and Forecast (2017-2028)
6.3.4 Mexico Tardive Dyskinesia (TD) Treatment Drugs Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7 Europe by Country, by Type, and by Application
7.1 Europe Tardive Dyskinesia (TD) Treatment Drugs Revenue by Type (2017-2028)
7.2 Europe Tardive Dyskinesia (TD) Treatment Drugs Revenue by Application (2017-2028)
7.3 Europe Tardive Dyskinesia (TD) Treatment Drugs Market Size by Country
7.3.1 Europe Tardive Dyskinesia (TD) Treatment Drugs Revenue by Country (2017-2028)
7.3.2 Germany Tardive Dyskinesia (TD) Treatment Drugs Market Size and Forecast (2017-2028)
7.3.3 France Tardive Dyskinesia (TD) Treatment Drugs Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Tardive Dyskinesia (TD) Treatment Drugs Market Size and Forecast (2017-2028)
7.3.5 Russia Tardive Dyskinesia (TD) Treatment Drugs Market Size and Forecast (2017-2028)
7.3.6 Italy Tardive Dyskinesia (TD) Treatment Drugs Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Tardive Dyskinesia (TD) Treatment Drugs Revenue by Type (2017-2028)
8.2 Asia-Pacific Tardive Dyskinesia (TD) Treatment Drugs Revenue by Application (2017-2028)
8.3 Asia-Pacific Tardive Dyskinesia (TD) Treatment Drugs Market Size by Region
8.3.1 Asia-Pacific Tardive Dyskinesia (TD) Treatment Drugs Revenue by Region (2017-2028)
8.3.2 China Tardive Dyskinesia (TD) Treatment Drugs Market Size and Forecast (2017-2028)
8.3.3 Japan Tardive Dyskinesia (TD) Treatment Drugs Market Size and Forecast (2017-2028)
8.3.4 South Korea Tardive Dyskinesia (TD) Treatment Drugs Market Size and Forecast (2017-2028)
8.3.5 India Tardive Dyskinesia (TD) Treatment Drugs Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Tardive Dyskinesia (TD) Treatment Drugs Market Size and Forecast (2017-2028)
8.3.7 Australia Tardive Dyskinesia (TD) Treatment Drugs Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9 South America by Country, by Type, and by Application
9.1 South America Tardive Dyskinesia (TD) Treatment Drugs Revenue by Type (2017-2028)
9.2 South America Tardive Dyskinesia (TD) Treatment Drugs Revenue by Application (2017-2028)
9.3 South America Tardive Dyskinesia (TD) Treatment Drugs Market Size by Country
9.3.1 South America Tardive Dyskinesia (TD) Treatment Drugs Revenue by Country (2017-2028)
9.3.2 Brazil Tardive Dyskinesia (TD) Treatment Drugs Market Size and Forecast (2017-2028)
9.3.3 Argentina Tardive Dyskinesia (TD) Treatment Drugs Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Tardive Dyskinesia (TD) Treatment Drugs Revenue by Type (2017-2028)
10.2 Middle East & Africa Tardive Dyskinesia (TD) Treatment Drugs Revenue by Application (2017-2028)
10.3 Middle East & Africa Tardive Dyskinesia (TD) Treatment Drugs Market Size by Country
10.3.1 Middle East & Africa Tardive Dyskinesia (TD) Treatment Drugs Revenue by Country (2017-2028)
10.3.2 Turkey Tardive Dyskinesia (TD) Treatment Drugs Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Tardive Dyskinesia (TD) Treatment Drugs Market Size and Forecast (2017-2028)
10.3.4 UAE Tardive Dyskinesia (TD) Treatment Drugs Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
11 Research Findings and Conclusion
12 Appendix
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Tardive Dyskinesia (TD) Treatment Drugs Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Tardive Dyskinesia (TD) Treatment Drugs Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Tardive Dyskinesia (TD) Treatment Drugs Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Tardive Dyskinesia (TD) Treatment Drugs Revenue (USD Million) by Region (2017-2022)
Table 5. Global Tardive Dyskinesia (TD) Treatment Drugs Revenue Market Share by Region (2023-2028)
Table 6. Neurocrine Biosciences, Inc. Corporate Information, Head Office, and Major Competitors
Table 7. Neurocrine Biosciences, Inc. Major Business
Table 8. Neurocrine Biosciences, Inc. Tardive Dyskinesia (TD) Treatment Drugs Product and Solutions
Table 9. Neurocrine Biosciences, Inc. Tardive Dyskinesia (TD) Treatment Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Teva Pharmaceutical Industries Corporate Information, Head Office, and Major Competitors
Table 11. Teva Pharmaceutical Industries Major Business
Table 12. Teva Pharmaceutical Industries Tardive Dyskinesia (TD) Treatment Drugs Product and Solutions
Table 13. Teva Pharmaceutical Industries Tardive Dyskinesia (TD) Treatment Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Pfizer Inc. Corporate Information, Head Office, and Major Competitors
Table 15. Pfizer Inc. Major Business
Table 16. Pfizer Inc. Tardive Dyskinesia (TD) Treatment Drugs Product and Solutions
Table 17. Pfizer Inc. Tardive Dyskinesia (TD) Treatment Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Biogen Corporate Information, Head Office, and Major Competitors
Table 19. Biogen Major Business
Table 20. Biogen Tardive Dyskinesia (TD) Treatment Drugs Product and Solutions
Table 21. Biogen Tardive Dyskinesia (TD) Treatment Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Novartis AG Corporate Information, Head Office, and Major Competitors
Table 23. Novartis AG Major Business
Table 24. Novartis AG Tardive Dyskinesia (TD) Treatment Drugs Product and Solutions
Table 25. Novartis AG Tardive Dyskinesia (TD) Treatment Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 27. AstraZeneca Major Business
Table 28. AstraZeneca Tardive Dyskinesia (TD) Treatment Drugs Product and Solutions
Table 29. AstraZeneca Tardive Dyskinesia (TD) Treatment Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. GlaxoSmithKline plc. Corporate Information, Head Office, and Major Competitors
Table 31. GlaxoSmithKline plc. Major Business
Table 32. GlaxoSmithKline plc. Tardive Dyskinesia (TD) Treatment Drugs Product and Solutions
Table 33. GlaxoSmithKline plc. Tardive Dyskinesia (TD) Treatment Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Bayer AG Corporate Information, Head Office, and Major Competitors
Table 35. Bayer AG Major Business
Table 36. Bayer AG Tardive Dyskinesia (TD) Treatment Drugs Product and Solutions
Table 37. Bayer AG Tardive Dyskinesia (TD) Treatment Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Sanofi Corporate Information, Head Office, and Major Competitors
Table 39. Sanofi Major Business
Table 40. Sanofi Tardive Dyskinesia (TD) Treatment Drugs Product and Solutions
Table 41. Sanofi Tardive Dyskinesia (TD) Treatment Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Global Tardive Dyskinesia (TD) Treatment Drugs Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 43. Global Tardive Dyskinesia (TD) Treatment Drugs Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 44. Breakdown of Tardive Dyskinesia (TD) Treatment Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 45. Tardive Dyskinesia (TD) Treatment Drugs Players Head Office, Products and Services Provided
Table 46. Tardive Dyskinesia (TD) Treatment Drugs Mergers & Acquisitions in the Past Five Years
Table 47. Tardive Dyskinesia (TD) Treatment Drugs New Entrants and Expansion Plans
Table 48. Global Tardive Dyskinesia (TD) Treatment Drugs Revenue (USD Million) by Type (2017-2022)
Table 49. Global Tardive Dyskinesia (TD) Treatment Drugs Revenue Share by Type (2017-2022)
Table 50. Global Tardive Dyskinesia (TD) Treatment Drugs Revenue Forecast by Type (2023-2028)
Table 51. Global Tardive Dyskinesia (TD) Treatment Drugs Revenue by Application (2017-2022)
Table 52. Global Tardive Dyskinesia (TD) Treatment Drugs Revenue Forecast by Application (2023-2028)
Table 53. North America Tardive Dyskinesia (TD) Treatment Drugs Revenue by Type (2017-2022) & (USD Million)
Table 54. North America Tardive Dyskinesia (TD) Treatment Drugs Revenue by Type (2023-2028) & (USD Million)
Table 55. North America Tardive Dyskinesia (TD) Treatment Drugs Revenue by Application (2017-2022) & (USD Million)
Table 56. North America Tardive Dyskinesia (TD) Treatment Drugs Revenue by Application (2023-2028) & (USD Million)
Table 57. North America Tardive Dyskinesia (TD) Treatment Drugs Revenue by Country (2017-2022) & (USD Million)
Table 58. North America Tardive Dyskinesia (TD) Treatment Drugs Revenue by Country (2023-2028) & (USD Million)
Table 59. Europe Tardive Dyskinesia (TD) Treatment Drugs Revenue by Type (2017-2022) & (USD Million)
Table 60. Europe Tardive Dyskinesia (TD) Treatment Drugs Revenue by Type (2023-2028) & (USD Million)
Table 61. Europe Tardive Dyskinesia (TD) Treatment Drugs Revenue by Application (2017-2022) & (USD Million)
Table 62. Europe Tardive Dyskinesia (TD) Treatment Drugs Revenue by Application (2023-2028) & (USD Million)
Table 63. Europe Tardive Dyskinesia (TD) Treatment Drugs Revenue by Country (2017-2022) & (USD Million)
Table 64. Europe Tardive Dyskinesia (TD) Treatment Drugs Revenue by Country (2023-2028) & (USD Million)
Table 65. Asia-Pacific Tardive Dyskinesia (TD) Treatment Drugs Revenue by Type (2017-2022) & (USD Million)
Table 66. Asia-Pacific Tardive Dyskinesia (TD) Treatment Drugs Revenue by Type (2023-2028) & (USD Million)
Table 67. Asia-Pacific Tardive Dyskinesia (TD) Treatment Drugs Revenue by Application (2017-2022) & (USD Million)
Table 68. Asia-Pacific Tardive Dyskinesia (TD) Treatment Drugs Revenue by Application (2023-2028) & (USD Million)
Table 69. Asia-Pacific Tardive Dyskinesia (TD) Treatment Drugs Revenue by Region (2017-2022) & (USD Million)
Table 70. Asia-Pacific Tardive Dyskinesia (TD) Treatment Drugs Revenue by Region (2023-2028) & (USD Million)
Table 71. South America Tardive Dyskinesia (TD) Treatment Drugs Revenue by Type (2017-2022) & (USD Million)
Table 72. South America Tardive Dyskinesia (TD) Treatment Drugs Revenue by Type (2023-2028) & (USD Million)
Table 73. South America Tardive Dyskinesia (TD) Treatment Drugs Revenue by Application (2017-2022) & (USD Million)
Table 74. South America Tardive Dyskinesia (TD) Treatment Drugs Revenue by Application (2023-2028) & (USD Million)
Table 75. South America Tardive Dyskinesia (TD) Treatment Drugs Revenue by Country (2017-2022) & (USD Million)
Table 76. South America Tardive Dyskinesia (TD) Treatment Drugs Revenue by Country (2023-2028) & (USD Million)
Table 77. Middle East & Africa Tardive Dyskinesia (TD) Treatment Drugs Revenue by Type (2017-2022) & (USD Million)
Table 78. Middle East & Africa Tardive Dyskinesia (TD) Treatment Drugs Revenue by Type (2023-2028) & (USD Million)
Table 79. Middle East & Africa Tardive Dyskinesia (TD) Treatment Drugs Revenue by Application (2017-2022) & (USD Million)
Table 80. Middle East & Africa Tardive Dyskinesia (TD) Treatment Drugs Revenue by Application (2023-2028) & (USD Million)
Table 81. Middle East & Africa Tardive Dyskinesia (TD) Treatment Drugs Revenue by Country (2017-2022) & (USD Million)
Table 82. Middle East & Africa Tardive Dyskinesia (TD) Treatment Drugs Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Tardive Dyskinesia (TD) Treatment Drugs Picture
Figure 2. Global Tardive Dyskinesia (TD) Treatment Drugs Revenue Market Share by Type in 2021
Figure 3. Valbenazine
Figure 4. Deutetrabenazine
Figure 5. Tardive Dyskinesia (TD) Treatment Drugs Revenue Market Share by Application in 2021
Figure 6. Hospitals Picture
Figure 7. Clinic Picture
Figure 8. Others Picture
Figure 9. Global Tardive Dyskinesia (TD) Treatment Drugs Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 10. Global Tardive Dyskinesia (TD) Treatment Drugs Revenue and Forecast (2017-2028) & (USD Million)
Figure 11. Global Tardive Dyskinesia (TD) Treatment Drugs Revenue Market Share by Region (2017-2028)
Figure 12. Global Tardive Dyskinesia (TD) Treatment Drugs Revenue Market Share by Region in 2021
Figure 13. North America Tardive Dyskinesia (TD) Treatment Drugs Revenue (USD Million) and Growth Rate (2017-2028)
Figure 14. Europe Tardive Dyskinesia (TD) Treatment Drugs Revenue (USD Million) and Growth Rate (2017-2028)
Figure 15. Asia-Pacific Tardive Dyskinesia (TD) Treatment Drugs Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. South America Tardive Dyskinesia (TD) Treatment Drugs Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Middle East and Africa Tardive Dyskinesia (TD) Treatment Drugs Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Tardive Dyskinesia (TD) Treatment Drugs Market Drivers
Figure 19. Tardive Dyskinesia (TD) Treatment Drugs Market Restraints
Figure 20. Tardive Dyskinesia (TD) Treatment Drugs Market Trends
Figure 21. Neurocrine Biosciences, Inc. Recent Developments and Future Plans
Figure 22. Teva Pharmaceutical Industries Recent Developments and Future Plans
Figure 23. Pfizer Inc. Recent Developments and Future Plans
Figure 24. Biogen Recent Developments and Future Plans
Figure 25. Novartis AG Recent Developments and Future Plans
Figure 26. AstraZeneca Recent Developments and Future Plans
Figure 27. GlaxoSmithKline plc. Recent Developments and Future Plans
Figure 28. Bayer AG Recent Developments and Future Plans
Figure 29. Sanofi Recent Developments and Future Plans
Figure 30. Global Tardive Dyskinesia (TD) Treatment Drugs Revenue Share by Players in 2021
Figure 31. Tardive Dyskinesia (TD) Treatment Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 32. Global Top 3 Players Tardive Dyskinesia (TD) Treatment Drugs Revenue Market Share in 2021
Figure 33. Global Top 10 Players Tardive Dyskinesia (TD) Treatment Drugs Revenue Market Share in 2021
Figure 34. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 35. Global Tardive Dyskinesia (TD) Treatment Drugs Revenue Share by Type in 2021
Figure 36. Global Tardive Dyskinesia (TD) Treatment Drugs Market Share Forecast by Type (2023-2028)
Figure 37. Global Tardive Dyskinesia (TD) Treatment Drugs Revenue Share by Application in 2021
Figure 38. Global Tardive Dyskinesia (TD) Treatment Drugs Market Share Forecast by Application (2023-2028)
Figure 39. North America Tardive Dyskinesia (TD) Treatment Drugs Sales Market Share by Type (2017-2028)
Figure 40. North America Tardive Dyskinesia (TD) Treatment Drugs Sales Market Share by Application (2017-2028)
Figure 41. North America Tardive Dyskinesia (TD) Treatment Drugs Revenue Market Share by Country (2017-2028)
Figure 42. United States Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Canada Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Mexico Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Europe Tardive Dyskinesia (TD) Treatment Drugs Sales Market Share by Type (2017-2028)
Figure 46. Europe Tardive Dyskinesia (TD) Treatment Drugs Sales Market Share by Application (2017-2028)
Figure 47. Europe Tardive Dyskinesia (TD) Treatment Drugs Revenue Market Share by Country (2017-2028)
Figure 48. Germany Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. France Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. United Kingdom Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Russia Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Italy Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Asia-Pacific Tardive Dyskinesia (TD) Treatment Drugs Sales Market Share by Type (2017-2028)
Figure 54. Asia-Pacific Tardive Dyskinesia (TD) Treatment Drugs Sales Market Share by Application (2017-2028)
Figure 55. Asia-Pacific Tardive Dyskinesia (TD) Treatment Drugs Revenue Market Share by Region (2017-2028)
Figure 56. China Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Japan Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. South Korea Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. India Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Southeast Asia Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Australia Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. South America Tardive Dyskinesia (TD) Treatment Drugs Sales Market Share by Type (2017-2028)
Figure 63. South America Tardive Dyskinesia (TD) Treatment Drugs Sales Market Share by Application (2017-2028)
Figure 64. South America Tardive Dyskinesia (TD) Treatment Drugs Revenue Market Share by Country (2017-2028)
Figure 65. Brazil Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Argentina Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Middle East and Africa Tardive Dyskinesia (TD) Treatment Drugs Sales Market Share by Type (2017-2028)
Figure 68. Middle East and Africa Tardive Dyskinesia (TD) Treatment Drugs Sales Market Share by Application (2017-2028)
Figure 69. Middle East and Africa Tardive Dyskinesia (TD) Treatment Drugs Revenue Market Share by Country (2017-2028)
Figure 70. Turkey Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Saudi Arabia Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. UAE Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Methodology
Figure 74. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
